Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Seres Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 99 | 93 | −6 |
| Shares | 85.8M | 69.1M | −16.6M (−19.4%) |
| Value | $66.3M | $50.0M | −$16.3M (−24.6%) |
New holders (21)
Institutions that held Seres Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Verition Fund Management LLC | 314,177 | $227.4K | 0.00% |
| Centiva Capital, LP | 187,800 | $135.9K | 0.01% |
| Point72 Asia (Singapore) Pte. Ltd. | 127,634 | $92.4K | 0.02% |
| Y-Intercept (Hong Kong) Ltd | 123,590 | $89.5K | 0.00% |
| Paloma Partners Management Co | 111,032 | $80.4K | 0.01% |
| HRT Financial LP | 94,972 | $68.0K | 0.00% |
| Point72 (DIFC) Ltd | 87,754 | $63.5K | 0.01% |
| Schonfeld Strategic Advisors LLC | 60,100 | $43.5K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 50,437 | $36.5K | 0.00% |
| JustInvest LLC | 26,522 | $19.2K | 0.00% |
| Evercore Wealth Management, LLC | 25,000 | $18.1K | 0.00% |
| Arete Wealth Advisors, LLC | 22,150 | $16.0K | 0.00% |
| Balyasny Asset Management LLC | 19,705 | $14.3K | 0.00% |
| Avantax Advisory Services, Inc. | 16,679 | $12.1K | 0.00% |
| Jump Financial, LLC | 10,236 | $7.41K | 0.00% |
| Macquarie Group Ltd | 4,945 | $3.58K | 0.00% |
| EverSource Wealth Advisors, LLC | 666 | $892 | 0.00% |
| Allspring Global Investments Holdings, LLC | 611 | $442 | 0.00% |
| Farther Finance Advisors, LLC | 204 | $147 | 0.00% |
| GWM Advisors LLC | 200 | $145 | 0.00% |
| Whittier Trust Co | 30 | $21 | 0.00% |
Sold out (27)
Institutions that held Seres Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.